

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EVEREST MEDICINES

云 頂 新 耀

Everest Medicines Limited

雲 頂 新 耀 有 限 公 司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 1952)

RESIGNATION OF JOINT COMPANY SECRETARY

The board of directors (the “**Board**”) of Everest Medicines Limited (the “**Company**”) announces that Ms. Yin Yin (印茵) (“**Ms. Yin**”) has tendered her resignation as a joint company secretary of the Company with effect from January 31, 2022 due to personal reason.

Ms. Yin confirmed that she has no disagreement with the Board and there are no matters in relation to her resignation that need to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Upon Ms. Yin’s resignation as a joint company secretary of the Company, the other joint company secretary of the Company, Ms. Lau Yee Wa (劉綺華), who possesses the requisite qualification and experience as required under Rule 3.28 of the Rules Governing the Listing of Securities on the Stock Exchange, will remain in office and act as the company secretary of the Company.

The Board would like to take this opportunity to express its sincere gratitude to Ms. Yin for her valuable contributions to the Company during her tenure of service.

By Order of the Board
Everest Medicines Limited
Wei Fu
Chairman and Executive Director

Hong Kong, January 31, 2022

As at the date of this announcement, the Board comprises Mr. Wei Fu as Chairman and Executive Director, Dr. Kerry Levan Blanchard, Mr. Ian Ying Woo and Mr. Xiaofan Zhang as Executive Directors, Mr. Yubo Gong and Ms. Lan Kang as Non-executive Directors, and Mr. Bo Tan, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.